Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Evaluation of denosumab in adult oncology patients for the prevention of skeletal related events across a large academic health system.

Michelle R Sproat,Bradley Burton,Catherine Burdalski, Timothy Porter, Celia Proctor, Michael Goldenhorn, Kofi Andoh,Steven Gilmore

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners（2023）

Cited 0|Views2
No score
Abstract
Within our health system, denosumab is restricted to those who meet formulary restrictions. Additional education is recommended to help limit the use of denosumab, specifically in MM, to reduce drug costs when zoledronic acid is also an appropriate first-line agent.
More
Translated text
Key words
Denosumab,alternative site of care,drug cost,skeletal related events,zoledronic acid
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined